RxDoctor Payments Data

Stephen Winfield, MD

Family Medicine · Champlain, NYNPI 1992156970

Payments from drug & device makers

$3,186in general payments, 2019–2025

Across 160 payments — averaging $19.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$524
  • AstraZeneca$500
  • Novo Nordisk$496
  • Amgen$289
  • Pfizer$254
  • Lilly USA, LLC$244
  • plus $878 from 15 others

What the payments were for

  • Food & beverage$3,186100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,186 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$179,568
Medicare patients
389
Services billed
1,913

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban92$135,111
OzempicSemaglutide89$112,262
Trelegy ElliptaFluticasone/Umeclidin/Vilanter104$94,591
JardianceEmpagliflozin48$72,728
FarxigaDapagliflozin Propanediol29$49,091
TrulicityDulaglutide30$46,195
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$32,129
WegovySemaglutide16$26,363
JanuviaSitagliptin Phosphate12$20,271
XareltoRivaroxaban13$14,078
Repatha SyringeEvolocumab11$13,880
JubliaEfinaconazole15$11,762
Incruse ElliptaUmeclidinium Bromide12$8,260
VascepaIcosapent Ethyl14$6,475
Breo ElliptaFluticasone/Vilanterol15$5,965

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$496$138,625105 claims
PfizerEliquis$254$135,11192 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta$167$108,817131 claims
AstraZenecaFarxiga, Breztri Aerosphere$500$81,22061 claims
Boehringer IngelheimJardiance$32$72,72848 claims
Lilly USA, LLCTrulicity$244$46,19530 claims
MerckJanuvia$18$20,27112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.

Other family medicine in Champlain

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →